Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection

Identifieur interne : 001C08 ( Main/Exploration ); précédent : 001C07; suivant : 001C09

Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection

Auteurs : Raphael Levi [Israël] ; Ruth Arnon [Israël]

Source :

RBID : ISTEX:4699D943F8EA1D9B0190737276949ED32CF0B770

English descriptors

Abstract

Abstract: Synthetic vaccines utilize specific antigenic epitopes in order to elicit a protective immune response. In this work we examined the immunogenicity of chimeric proteins expressing influenza epitopes and their ability, as single products or in various combinations, to protect mice from viral challenge. Oligonucleotides coding for three epitopes (HA91-108, NP55-69 and NP147-158) stimulating B cells, T helper cells and cytotoxic T lymphocytes (CTLs), respectively, were individually inserted into the flagellin gene of a Salmonella vaccine strain. Immunization of mice with the resultant hybrid flagella resulted in a specific humoral or cellular response. The protective efficacy of the chimeric flagella was evaluated by intranasal immunization of mice, without any adjuvant, and subsequent challenge with infectious virus. The construct containing the B-cell epitope by itself led to partial protection. However, the addition of the two T-cell epitopes augmented the protection in a significant manner. The protective immunity conferred by this combined vaccine, comprising the three epitopes, persisted for at least 7 months after the last boost, and was effective against several influenza A strains. Furthermore, this vaccine fully protected mice from a lethal challenge, and enhanced their recovery process. Our results indicate that stimulation of the different arms of the immune system is required for effective anti-influenza response, and demonstrate the applicability of such synthetic recombinant approach for preparing a broad spectrum influenza vaccine.

Url:
DOI: 10.1016/0264-410X(95)00088-I


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection</title>
<author>
<name sortKey="Levi, Raphael" sort="Levi, Raphael" uniqKey="Levi R" first="Raphael" last="Levi">Raphael Levi</name>
</author>
<author>
<name sortKey="Arnon, Ruth" sort="Arnon, Ruth" uniqKey="Arnon R" first="Ruth" last="Arnon">Ruth Arnon</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4699D943F8EA1D9B0190737276949ED32CF0B770</idno>
<date when="1996" year="1996">1996</date>
<idno type="doi">10.1016/0264-410X(95)00088-I</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-52N52DG4-4/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000966</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000966</idno>
<idno type="wicri:Area/Istex/Curation">000966</idno>
<idno type="wicri:Area/Istex/Checkpoint">000987</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000987</idno>
<idno type="wicri:doubleKey">0264-410X:1996:Levi R:synthetic:recombinant:influenza</idno>
<idno type="wicri:Area/Main/Merge">001C76</idno>
<idno type="wicri:Area/Main/Curation">001C08</idno>
<idno type="wicri:Area/Main/Exploration">001C08</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection</title>
<author>
<name sortKey="Levi, Raphael" sort="Levi, Raphael" uniqKey="Levi R" first="Raphael" last="Levi">Raphael Levi</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot</wicri:regionArea>
<wicri:noRegion>Rehovot</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Arnon, Ruth" sort="Arnon, Ruth" uniqKey="Arnon R" first="Ruth" last="Arnon">Ruth Arnon</name>
<affiliation></affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot</wicri:regionArea>
<wicri:noRegion>Rehovot</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Vaccine</title>
<title level="j" type="abbrev">JVAC</title>
<idno type="ISSN">0264-410X</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1996">1996</date>
<biblScope unit="volume">14</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="85">85</biblScope>
<biblScope unit="page" to="92">92</biblScope>
</imprint>
<idno type="ISSN">0264-410X</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Allantoic cavity</term>
<term>Allantoic fluid</term>
<term>Antiviral immunity</term>
<term>Arnon</term>
<term>Arnon table</term>
<term>Body weight</term>
<term>Cellular immunity</term>
<term>Cellular response</term>
<term>Challenge infection</term>
<term>Chimeric</term>
<term>Chimeric flagella</term>
<term>Chimeric proteins</term>
<term>Cholera toxin</term>
<term>Control group</term>
<term>Cytotoxic</term>
<term>Different subpopulations</term>
<term>Effective protection</term>
<term>Epitope</term>
<term>Flagellin</term>
<term>Flagellin gene</term>
<term>Flagellins</term>
<term>Flagellum</term>
<term>Helper cells</term>
<term>Hybrid flagellins</term>
<term>Immune</term>
<term>Immune response</term>
<term>Immune system</term>
<term>Immunization</term>
<term>Immunizing agent</term>
<term>Immunol</term>
<term>Influenza</term>
<term>Influenza epitopes</term>
<term>Influenza infection</term>
<term>Influenza nucleoprotein</term>
<term>Influenza strains</term>
<term>Influenza vaccine</term>
<term>Influenza virus</term>
<term>Influenza viruses</term>
<term>Intranasal</term>
<term>Intranasal administration</term>
<term>Intranasal immunization</term>
<term>Intranasal vaccination</term>
<term>Last immunization</term>
<term>Lethal challenge</term>
<term>Lethal dose</term>
<term>Lethal dose challenge</term>
<term>Levi</term>
<term>Light microscope</term>
<term>Lymphocyte</term>
<term>Lysis</term>
<term>Massive lymphocyte infiltration</term>
<term>Massive perivascular</term>
<term>Mice intranasally</term>
<term>Mice vaccinated</term>
<term>Mouse</term>
<term>Neutralizing antibodies</term>
<term>Nonparametric method</term>
<term>Nucleoprotein</term>
<term>Oligonucleotides coding</term>
<term>Open symbols</term>
<term>Partial protection</term>
<term>Peptide</term>
<term>Plasmid vector</term>
<term>Present study</term>
<term>Proliferative response</term>
<term>Protective effect</term>
<term>Protective immunity</term>
<term>Recombinant</term>
<term>Recombinant bacteria</term>
<term>Recombinant flagellin</term>
<term>Recombinant flagellins</term>
<term>Recombinant nucleoprotein</term>
<term>Recovery process</term>
<term>Respiratory tract</term>
<term>Salmonella</term>
<term>Salmonella flagellin</term>
<term>Salmonella vaccine strain</term>
<term>Serum samples</term>
<term>Stanford university</term>
<term>Subsequent challenge</term>
<term>Surface antigen</term>
<term>Synthetic peptide</term>
<term>Synthetic peptides</term>
<term>Synthetic vaccine</term>
<term>Synthetic vaccines</term>
<term>Target cells</term>
<term>Triple combination</term>
<term>Untreated control</term>
<term>Vaccination</term>
<term>Vaccine</term>
<term>Vaccine development</term>
<term>Vaccine strain</term>
<term>Various combinations</term>
<term>Viral</term>
<term>Viral challenge</term>
<term>Viral surface antigens</term>
<term>Weight loss</term>
<term>Weizmann institute</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: Synthetic vaccines utilize specific antigenic epitopes in order to elicit a protective immune response. In this work we examined the immunogenicity of chimeric proteins expressing influenza epitopes and their ability, as single products or in various combinations, to protect mice from viral challenge. Oligonucleotides coding for three epitopes (HA91-108, NP55-69 and NP147-158) stimulating B cells, T helper cells and cytotoxic T lymphocytes (CTLs), respectively, were individually inserted into the flagellin gene of a Salmonella vaccine strain. Immunization of mice with the resultant hybrid flagella resulted in a specific humoral or cellular response. The protective efficacy of the chimeric flagella was evaluated by intranasal immunization of mice, without any adjuvant, and subsequent challenge with infectious virus. The construct containing the B-cell epitope by itself led to partial protection. However, the addition of the two T-cell epitopes augmented the protection in a significant manner. The protective immunity conferred by this combined vaccine, comprising the three epitopes, persisted for at least 7 months after the last boost, and was effective against several influenza A strains. Furthermore, this vaccine fully protected mice from a lethal challenge, and enhanced their recovery process. Our results indicate that stimulation of the different arms of the immune system is required for effective anti-influenza response, and demonstrate the applicability of such synthetic recombinant approach for preparing a broad spectrum influenza vaccine.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Israël</li>
</country>
</list>
<tree>
<country name="Israël">
<noRegion>
<name sortKey="Levi, Raphael" sort="Levi, Raphael" uniqKey="Levi R" first="Raphael" last="Levi">Raphael Levi</name>
</noRegion>
<name sortKey="Arnon, Ruth" sort="Arnon, Ruth" uniqKey="Arnon R" first="Ruth" last="Arnon">Ruth Arnon</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C08 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C08 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:4699D943F8EA1D9B0190737276949ED32CF0B770
   |texte=   Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021